Phase I Dose Finding Study for Melatonin in Pediatric Oncology Patients With Relapsed Solid Tumors
Status:
Completed
Trial end date:
2017-12-31
Target enrollment:
Participant gender:
Summary
This study will evaluate dose escalation of melatonin in pediatric oncology patients with
relapsed solid tumors. The purpose of this study is to determine the safety of melatonin at a
dose up to 20 mg daily, as well as to determine the maximum tolerated dose of melatonin.